Persa OD, Schatton K, Rubben A, Berking C, et al. Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients. J Immunother 2021 May 24. pii: 00002371-900000000-99338.
PMID: 34028389